The Financial Times reported, on Wednesday night, that Oxford University and AstraZeneca had begun work to produce a version of their vaccine for the Corona virus targeting the mutant Omicron.

Sandy Douglas, head of a research group in Oxford, told the “Financial Times” that preliminary steps have been taken to produce an updated vaccine, should it be needed, in cooperation with their partners in AstraZeneca.

He added: “Adenovirus-based vaccines (such as those made by Oxford / AstraZeneca) can in principle be used to counter any new mutant more quickly than some may have previously realized.”

Countries across Europe considered imposing new restrictions on movement, while US President Joe Biden called in doctors from the army to support hospitals and fight the mutated Omicron from the Corona virus, which swept the world days before the second Christmas in the shadow of the pandemic.